In a nutshell The authors looked at the long-term results of total lymphoid irradiation for patients with relapsed or unresponsive Hodgkin lymphoma. The authors concluded that total lymphoid irradiation combined with high-dose chemotherapy is a safe and effective treatment for patients with relapsed or unresponsive Hodgkin lymphoma. Some background...
Read More
In a nutshell This phase 2 trial aims to test the safety and effectiveness of treatment with irutinib (Imbruvica) and nivolumab (Opdivo) in patients with recurrent (when the cancer comes back) Hodgkin lymphoma or that has not responded to the first line treatment. The main outcome to be measure will be the response of the cancer to treatment. This...
Read More
Two blood cancers with such similar names, Non-Hodgkin and Hodgkin Lymphoma, is bound to cause confusion. The Dana Farber Cancer Institute has created a great infographic to help clear up any...
Read More
In a nutshell The authors looked at patient outcomes for those who had a late relapse of Hodgkin lymphoma. The authors suggested that survivors are at higher risk of disease recurrence than the general population, and should continue to monitor their disease status. Some background Hodgkin lymphoma (HL) is generally considered a curable disease....
Read More
In a nutshell This review looked at the ability of F-luoro-2-deoxy-D-glucose positron emission topography (FDG-PET) to predict complete disease remission in patients with Hodgkin lymphoma who have completed first-line treatment. The authors suggested that FDG-PET may not be fully accurate at predicting remission in patients who have completed...
Read More
In a nutshell The authors examined the safety and effectiveness of nivolumab (Opdivo) in patients with relapsed Hodgkin’s lymphoma after allogenic stem cell transplantation. The authors concluded that this treatment is generally safe and effective. Some background Hodgkin’s lymphoma (HL) is generally considered curable. However,...
Read More
In a nutshell This study examined the outcomes of allogenic (donor) stem cell transplantation in two different time periods. The authors found that those treated in the later time period, 2009-2013, had better overall survival and fewer relapses, largely due to improvements in treatment options. Some background Hodgkin lymphoma is widely...
Read MoreIn a nutshell This study compared three sources of stem cells for patients receiving allogenic stem cell transplantation. The authors suggested that stem cells from familial haploidentical donors can lead to better patient outcomes. Some background Hodgkin lymphoma (HL) is generally considered curable. However, some cases do not respond to...
Read More
In a nutshell This study examined a treatment for advanced Hodgkin lymphoma, haploidentical stem cell transplantation with post-infusion cyclophosphamide (haplo-HSCT). The authors concluded that the use of haplo-HSCT is a valid treatment option for patients with advanced Hodgkin lymphoma (HL). Some background Hodgkin lymphoma is...
Read More
In a nutshell This study explored whether radiation therapy was necessary in patients with early-stage Hodgkin lymphoma. The study concluded that disease progression occurred more often in patients who did not undergo radiation. Some background The standard treatment option for early stage Hodgkin lymphoma is chemotherapy followed by radiation....
Read MoreIn a nutshell The authors compared two different intensities of chemotherapy regimens for use before allogenic stem cell transplantation. The authors suggested that the two treatments had similar patient outcomes, with more intense therapy having slightly better outcomes. Some background Hodgkin lymphoma (HL) is considered a curable disease....
Read More
In a nutshell The authors looked at patient characteristics, types of treatment, and clinical outcomes for patients with nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The study confirmed the positive long-term outcome of this disease. The authors suggested that it may be possible to reduce the intensity of the treatment without...
Read More
